The UK National Screening Committee has reinforced its evidence-based opposition to routine prostate cancer screening, releasing comprehensive position statements that challenge assumptions about how medical tests translate into population health programmes. The committee’s stance reflects a sophisticated understanding that screening decisions require far more than diagnostic accuracy. Two new position statements address the emerging landscape of multicancer detection tests and the role of surrogate outcomes in screening policy. The committee emphasises that effective screening programmes demand rigorous evaluation across multiple domains, including treatment effectiveness, population-level benefits, and harm-benefit analysis. This nuanced approach provides transparency for clinicians and policymakers navigating pressures to expand screening initiatives based solely on technological capability rather than demonstrated clinical benefit.
Was this article helpful?
